Return to CG81 Overview

Advanced breast cancer: diagnosis and treatment [CG81]

Measuring the use of this guidance

Recommendation: 1.1.6

On recurrence, consider reassessing oestrogen receptor (ER) and human epidermal growth factor 2 receptor (HER2) status if a change in receptor status will lead to a change in management.

What was measured: Proportion of NHS trusts in England that routinely perform HER2 testing for people with advanced breast cancer.
Data collection end: March 2017
93%
Area covered: England and Wales
Source: Royal College of Surgeons. National Audit of Breast Cancer in Older Patients.



 Return to CG81 Overview